Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared...

BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well...

Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive...

MONDAY, Oct. 21, 2024 -- For patients with acute ischemic stroke, social determinants of health (SDOH) are associated with the likelihood of...

Competitive: Bristol Myers Squibb: Working with Us Challenging. Meaningful. Life-changing. Those aren't words that are usually associated with a job....

BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings...

MONDAY, Nov. 4, 2024 -- For patients with severely calcified coronary lesions, routine treatment with orbital atherectomy prior to drug-eluting stent...

In the context of globalisation and modernisation, Việt Nam's healthcare sector is committed to enhancing service quality and expand international...

A drug used in cancer treatment has the potential to save the limbs of thousands of cardiac patients with blocked arteries, a study has found.

It will be a relief for women dealing with years of shortages of oestrogen patches.